<DOC>
	<DOCNO>NCT00918424</DOCNO>
	<brief_summary>Study evaluate safety tolerability OXC XR adjunctive therapy pediatric subject refractory partial epilepsy .</brief_summary>
	<brief_title>Long Term Study Evaluate Safety Tolerability Oxcarbazepine Extended Release ( OXC XR ) Adjunctive Therapy Pediatric Subjects With Refractory Partial Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>1 . Able provide write informed assent ( IAF ) , appropriate , write informed permission ( inform consent ( ICF ) require regional law regulation ) parent legallyauthorized representative ( LAR ) . 2 . Was eligible complete 804P107 study . 3 . Weight within 25 75 % weightforage percentile base National Center Health Statistics Growth Charts , less 15.0kg , enter 804P107 study . 4 . Able willing swallow whole tablet . 5 . Females childbearing potential ( FOCP ) either sexually inactive ( abstinent ) 14 day prior enter 804P107 804P107 , throughout study , four day follow last dose ; , sexually active , use one follow acceptable birth control method : 1 . Surgically sterile ( bilateral tubal ligation , hysterectomy , bilateral oophorectomy ) six month minimum ; 2 . Intrauterine device place least three month ; 3 . Barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose 804P107 study , throughout study , four day follow last dose ; 4 . Surgical sterilization partner ( vasectomy six month minimum ) ; 5 . Hormonal contraceptive addition barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose 804P107 study , throughout study , four day follow last dose . 1 . Meets criteria history major depressive manic episode , accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition Text Revision . 2 . Any history suicide intent and/or attempt . 3 . History presence clinically significant , chronic medical condition , especially contraindicate antiseizure medication , ( e.g. , neurological , gastrointestinal , endocrine , cardiovascular , pulmonary , hematological , immunologic , renal , hepatic metabolic disease ) may affect safety subject opinion Investigator . 4 . Use felbamate less 18 month continuous exposure prior screen 804P107 study continuous use throughout study . 5 . Frequent need rescue benzodiazepine ( 28 day period ) . 6 . Use diuretic sodiumlowering medication . 7 . History presence clinically significant laboratory , electrocardiogram ( ECG ) , vital sign abnormality may affect safety subject , opinion Investigator end study visit 804P107 study . 8 . Presence potential hepatic function impairment show , limited , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 time upper limit normal ( ULN ) , total bilirubin &gt; 1.5 time ULN , accord lab result 804P107 study . 9 . Presence suspect impairment renal function define serum creatinine â‰¥1.5 time ULN , accord lab result 804P107 study . 10 . Females pregnant lactating . 11 . Previous know hypersensitivity OXC relate drug , carbamazepine . 12 . Any reason , opinion Investigator , would prevent subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>